CTLA4 and isolated hemihyperplasia: The incidence of IH associated with the CTLA-4 inhibitor ipilimumab has been reported to increase with increasing drug dose [34], and the incidence of IH was approximately 1.8–3.3% in patients receiving low-dose ipilimumab (<3 mg/kg).